Johnson & Johnson (JNJ)

Solventum shares gain on strong Q2 revenue, earnings, and cash flow, buybacks, and improved guidance, with analysts raising price targets amid a discounted valuation versus med/tech peers.

These healthcare giants can deliver steady gains.

Investors may want to brace for turbulence. But these stocks should hold up well.

As the NASDAQ-100 corrects amid an AI CapEx-driven tech sell-off, sectors like healthcare and financials are rallying, boosting diversified value ETFs like the Schwab U.S. Large-Cap Value ETF (SCHV).

Johnson & Johnson (NYSE:JNJ) outlined its commercialization plans for the OTTAVA robotic surgical system after receiving U.S. Food and Drug Administration De Novo authorization, positioning the table-integrated platform as a long-term growth initiative in surgical robotics. The company said it

As stocks pull back from recent highs, lean into these three blue chip dividend stocks.

They have a combined 181 years of consecutive payout increases.

Abbott trades at a cheaper valuation but carries higher litigation risk, while J&J boasts superior profitability despite a pending talc settlement.

Johnson & Johnson (NYSE: JNJ) shares are edging higher on Friday as investors digest two major biotech pipeline moves.

Things are going well for the pharmaceutical giant.

Johnson & Johnson expands its biotech pipeline with Firefly Bio acquisition and a strategic partnership with Sail Biomedicines.

But is that performance sustainable?

Johnson & Johnson's revenue has grown modestly while Eli Lilly's revenue has nearly doubled in two years, narrowing a once-wide gap.

Johnson & Johnson reached a $5.5 billion agreement to resolve remaining federal and state talc litigation over ovarian cancer claims.